F S&P 500
5,242.75 -3.50 (-0.07%) F Dow Jones
39,629.00 -13.00 (-0.03%) F Nasdaq
18,245.25 -9.75 (-0.05%) E-mini Russell 2000 Index Futur
2,067.20 -0.70 (-0.03%) Petróleo
78.11 -0.15 (-0.19%) Oro
2,366.30 -8.70 (-0.37%)
Nascent Biotech, Inc. (NBIO)
Nascent Biotech, Inc.
631 US Hwy 1
Suite 407
North Palm Beach, FL 33408
United States
612 961 5656
https://www.nascentbiotech.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Sean Carrick | President, CEO, Secretary & Director | 252k | N/D | 1968 |
| Mr. Lowell Holden | CFO, Chief Accounting Officer & Director | 180k | N/D | 1943 |
| Dr. Mark C. Glassy Ph.D. | Founder | 43k | N/D | 1952 |
| Dr. Navpaul Singh M.D. | Chief Medical Consultant | N/D | N/D | N/D |
Descripción
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. The company has collaboration with Hypospray Pharma to develop an alternative delivery mechanism for patients who can benefit from Pritumumab. Nascent Biotech, Inc. is based in North Palm Beach, Florida.
Gestión corporativa
La calificación ISS Governance QuickScore de Nascent Biotech, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
